Hellstrom et al. revealed that ovarian cancer cell lines from stage III and IV patients with HER2 overexpression were sensitive to trastuzumab by antibody-dependent cellular cytotoxicity (ADCC) in vitro [11]. Here, ERBB2 is linked to ovarian carcinoma.